Crispr Therapeutics Ag (NQ: CRSP )
43.43 +0.29 (+0.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about Crispr Therapeutics Ag
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics...
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know
June 22, 2022
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over...
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
June 13, 2022
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic...
Why Orphan Drug Designation Offers Several Benefits
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following